Nikhil I. Khushalani
Moffitt Cancer Center(US)
Publications by Year
Research Areas
CAR-T cell therapy research, Cancer Immunotherapy and Biomarkers, Immunotherapy and Immune Responses, Melanoma and MAPK Pathways, Cutaneous Melanoma Detection and Management
Most-Cited Works
- → Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial(2015)2,648 cited
- → PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma(2018)1,358 cited
- → Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain(2018)1,297 cited
- → Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders(2015)654 cited
- → Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial(2020)513 cited
- → Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator’s Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial(2017)504 cited
- → Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial(2020)462 cited
- → Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma(2021)382 cited
- → Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma(2022)292 cited
- → Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study(2022)285 cited